Advertisement
Advertisement
FULC
Fulcrum Therapeutics, Inc. Common Stock
7.01
USDSponsored
+0.13
+1.89%
May 08, 15:59 UTC -4
Closed
After-Market
7.00
0.00
-0.07%
FULC Earnings Reports
Positive Surprise Ratio
FULC beat 21 of 28 last estimates.
75%
Next Report
Date of Next Report
Jul 27, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.29
Implied change from Q1 26 (Revenue/ EPS)
--
/+16.00%
Implied change from Q2 25 (Revenue/ EPS)
--
/+3.57%
Fulcrum Therapeutics, Inc. Common Stock earnings per share and revenue
On Apr 27, 2026, FULC reported earnings of -0.25 USD per share (EPS) for Q1 26, beating the estimate of -0.30 USD, resulting in a 17.79% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.53% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.29 USD, with revenue projected to reach -- USD, implying an increase of 16.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Fulcrum Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Fulcrum Therapeutics, Inc. Common Stock reported EPS of -$0.25, beating estimates by 17.79%, and revenue of $0.00, 0% as expectations.
How did the market react to Fulcrum Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -1.53%, changed from $7.84 before the earnings release to $7.72 the day after.
When is Fulcrum Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jul 27, 2026.
What are the forecasts for Fulcrum Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Fulcrum Therapeutics, Inc. Common Stock is expected to report EPS of -$0.29 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement